Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
EVE Health Group Limited ( (AU:EVE) ) has provided an update.
EVE Health Group has completed the first commercial manufacturing run of Libbo, its oral dissolving film treatment for erectile dysfunction, and delivered inventory to a national distribution partner, moving the product from development into commercial launch. With quality-assured stock now integrated into national warehousing, logistics and fulfilment systems, and telehealth prescribing and pharmacy channels in place, the company is positioned for imminent market entry, advancing its men’s health portfolio and underpinning its broader strategy to build scalable, revenue-generating pharmaceutical offerings in the sizable and growing erectile dysfunction treatment market.
The most recent analyst rating on (AU:EVE) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on EVE Health Group Limited stock, see the AU:EVE Stock Forecast page.
More about EVE Health Group Limited
EVE Health Group Limited (ASX: EVE) is an Australian life sciences company focused on developing and commercialising innovative pharmaceutical solutions in high-growth therapeutic areas. Its lead assets include Dyspro, a fast-acting cannabinoid-based pastille targeting dysmenorrhoea and endometriosis, and Libbo, an oral dissolving film treatment for erectile dysfunction designed to deliver rapid onset and improved patient convenience, both aimed at large, underserved global markets using proprietary formulation and delivery technologies.
Average Trading Volume: 415,056
Technical Sentiment Signal: Sell
Current Market Cap: A$5.7M
For detailed information about EVE stock, go to TipRanks’ Stock Analysis page.